41st Meeting of the Physicians
The Annual Meeting in figures4,393 participants from 82 countries
1,323 abstracts submitted
24 sponsored sessions
1,690 tweets using #EBMT15
New features including ‘Meet the expert', ‘social media’, or 'How I do' sessions were introduced with great success to this 41st edition.
31st Meeting of the Nurses GroupThe 31th Meeting of the Nurses Group began with a successful pre-meeting Education Day on Sunday where over 202 nurses attended from 41 countries. Experts from the field of nursing, medicine, psychology and JACIE operational management presented important nursing care issues including isolation, exercise following Haematopoietic Stem Cell Transplantation (HSCT), infections, graft failure and transfer of patients to Intensive Care Units.
Click here to view the sessions.
Stem cell transplantation has moved forward over the years and we now have a greater understanding of what is a complex treatment approach. Increasing numbers of patients are undergoing transplantation and cell therapy and the nursing care that accompanies HSCT, needs to be delivered in a safe and high quality manner. This year’s main conference, with almost 500 nurses attending from 43 counties, has been focused on patient’s safety and our role as nurses in minimizing the risk of errors that can occur. The presentation ‘Do we all do it the same way?’ – included a short documentary with nurses and doctors from a variety of European transplant centers, talking about patients safety and nursing in their centre. The Key Note Speaker for the Opening Lecture was Arto Helevuo, from Finland - an airline pilot who is an expert in Risk Management, talking about the importance of safety and linking in examples from alternative perspectives. The NG Research Committee also centered on safety with the session ‘Are Our Patients Safe in Research?’.
Click here to read the full chronicle.
14th Meeting of the Data Management GroupThe 14th Data Management Group meeting in Istanbul was attended by around 120 Data Managers from a variety of European countries and beyond and it really was an enjoyable event. The clinical education sessions were very informative and included presentations on: Molecular markers and cytogenetics; Understanding genetic and molecular markers in Lymphoma; DLIs – when & why used; Autoimmune – overview of cell therapy; Infections in Transplants; Transplant complications including VOD; How to evaluate response to treatment and relapse in Myeloma.
There were also some general data management sessions regarding: Clinical trials; Common data reporting problems; Changes in the Med-A ; Introduction to HSCT and the Med-A; Data Managers & Literature; Nursing in Paediatrics and an Update regarding the Registry System.
The Database Training sessions for ProMISe were held in the computer laboratory and were well attended. Data Management and Statistics posters were displayed in the poster hall. Many Data Managers and colleagues enjoyed the evening reception event.
Suggestions for the Data Management Programme next year in Valencia are very welcome - please send these to: email@example.com. The feedback report and presenters’ slides from this year’s meeting will be available on our website shortly. We look forward to seeing as many Data Managers as possible in Spain next year!
7th Meeting of the Quality Management GroupThe Quality Management meeting attracted excellent attendance to the sessions throughout Tuesday 24 April. Sessions included the workshop on validation, highlights of the 6th edition of the FACT-JACIE Standards, a special session on clinical outcome and benchmarking schemes in the US, UK and Italy, and a focus on research.
Alessandro Rambaldi's term as Chair of the Committee ended in Istanbul. He has ably served JACIE as Chair since 2012 and also sat as the Vice-chair for the previous 3 years. Alessandro will continue to support JACIE with his advice and experience. With effect from 22 March 2015, John Snowden takes up the position of Chair.
4th Cell Therapy DayThe program for the 4th edition of the Cell Therapy Day held on Monday March, 23rd, was jointly designed by members of the former Cell Processing Committee and members of the Local Organizing Committee.
It included 4 sessions with 4 speakers each, of which two sessions were jointly prepared and chaired by representatives of ISCT, the International Society for Cell Therapy and WBMT, the Worldwide Network for Blood & Marrow Transplantation.
Topics encompassed from optimization in the production of minimally manipulated products, including quality controls, to the design, manufacturing, and preclinical and clinical evaluation of substantially manipulated cell products. Progresses are still being made in procedures used to engineer minimally manipulated cell products, and these were illustrated in the first session. New applications of old and new forms of cell therapies, and regulatory issues that affect the practice and development of these approaches on both sides of the Atlantic Ocean were discussed in the joint EBMT-ISCT session.
The EBMT-WBMT joint session provided an opportunity to present an “outreach” initiative in the field of cell engineering, with the description of minimal requirements to set up a new cell processing facility.
Further presentations on training and competencies as well as process validation for cell engineering and quality controls provided the audience with practical and useful information that can be applied in their daily routine.
The last session provided a general overview of Europe’s policy and tools to support the development of cell therapies at large, illustrations of several projects closely related to hematopoietic stem cell transplantation and that benefit of European funding, as well as the presentation of EuCelLex, an initiative looking at ethical consequences of the implementation of the new regulatory framework over the last decade.
All sessions were well attended and lively, providing participants with an opportunity to gain updated and practical information.
In 2014, the Cell Processing Committee merged with the Immunobiology Working Party to form the newly established Cell Therapy & Immunobiology Working Party (CTIWP). The CTIWP will now take over the mission of working together with the Local Organizing Committee in order to prepare the 5th edition of the Cell Therapy Day to be held in 2016 at the 42nd EBMT Annual Meeting in Valencia, Spain.
4th Paediatric DayThe EBMT Annual Meeting saw the 4th Paediatric Day – a popular event in the EBMT calendar. This year, there were excellent programmes and presentations from the Paediatric Diseases Working Party and Inborn Errors Working Party. Each of the 4 sessions were well attended, with excellent presentations and many questions with discussion. Highlights were topics on TCR alpha/beta depletion outcomes for malignant and non-malignant disorders, and an update on current gene therapy. Also presented were data on PDWP and IEWP studies – particularly Myeloablative Chemoconditioning for Allogeneic SCT in children with ALL - An EBMT PDWP Study, the Duke-Eurocord Study on the outcomes of Cord Blood Transplantation for Leukodystrophies and Outcome after stem cell transplantation for severe combined immunodeficiency in Europe: Current results and future perspectives on behalf of the IEWP of the EBMT. There were many high quality presentations chosen from submitted abstracts. The Paediatric Day at EBMT gives attendees the opportunity to mix with fellow professionals, and importantly to hear about diseases with which they may be less familiar. The net-working is as important as the content – and with the paediatric sessions focused on one day – there are opportunities to re-new old acquaintances and forge new ones.
9th Patient, Family and Donor DayThe 9th EBMT Patient, Family & Donor Day has been held at the Celal Öker Hall within the Istanbul University Cerrahpasa Medical School. More than 150 attendees and 4 patient societies’ representatives participated in this very successful event. For patients, caregivers, transplant candidates and donors the event was an excellent opportunity to get information related to hematopoietic stem cell transplantation.
The Day was honored with the special appearance of Ahmet Ugurlu, an important Turkish actor who shared his experience as a patient being transplanted. Real life time problems have been discussed in view of the patients and healthy donors. Early and late post transplant complications have been described by local transplant physicians. Questions have been answered by both physicians and survivors of transplantation. Sharing experiences increased the awareness of the patients and families about their long adventure. What they listened, asked and discussed all were about real problems from the life after stem cell transplantation; from being a donor to sexual life after transplant.
We acknowledge Teoman Soysal, MD, head of both Dept. of Internal Medicine and Dept. of Hematology, for arrangement of the venue, and use of all resources of Cerrahpasa University Medical School.